Castle Biosciences launches MyUvealMelanoma website

Castle Biosciences Inc., a leading developer of prognostic tests for rare cancers, announced today the launch of, a website created to educate newly diagnosed patients, their families and healthcare providers about the most common form of eye cancer. MyUvealMelanoma tells the story of this disease, its treatment and the importance of prognostic testing, through the experience of patients who recently faced this devastating diagnosis first-hand.

Full Story →